NICF: Nanotechnology Investment and Commercialization Forum: Focus on Biotechnology and Pharmaceuticals, September 29th, SRI Conference Center, Menlo Park, CA

Speakers to Address Critical Stages of the Value Chain with Focus on Biotechnology and Pharmaceutical Ventures

Menlo Park, CA (PRWEB) September 19, 2004 -- Nanotechnology and New Venture Creation in Biotechnology and Pharmaceuticals" will be the topic of the September 29 event sponsored by the nanoSIG Nanotechnology Investment and Commercialization Forum. The panel of expert speakers will focus on the integration and the commercialization of nanotechnology within the pharmaceutical and biotechnology industries. The upcoming forum will be held from 10 AM-6 PM at the SRI Auditorium, 333 Ravenswood Ave, Menlo Park, CA.

Brian Sefton, Forum Chair, and Managing Director of nanoSIG said, "We expect the biotechnology and pharmaceutical topic to be of extreme interest to the investment community, researchers and entrepreneurs. We will have a stellar lineup of speakers to provide key information on how the application of nanotechnology techniques for molecular and atomic level engineering to biotechnology and pharmaceuticals is revolutionizing the creation of new therapeutics, tools and techniques. When commercialized, these new technologies form the core intellectual property of new market focused ventures."

Attendees will be investors, C-level business representatives, senior technical professionals, researchers and entrepreneurs, press, policy makers, economic development leaders, technology transfer experts, and more. Speakers for the Nanotechnology Investing and Commercialization Forum series include executives from leading companies and research institutions in biotechnology and pharmaceuticals.

Speakers will include:
• Dr. Gadi Behar, President & CEO of Silicom Ventures LLC
• Dr. Sam Doctors, CEO, ACET
• Dr. Regis Kelley, UCSF, QB3 and CBE
• Dr. Micheal Mueller, UC Discovery Grant Organization
• Dr. Jeff Rosner, Agilent
• Richard Trecartin, Dorsey and Whitney LLP
• Dr. Alexei Andreev, Draper Fisher, Jurvetson
• Dr. Joseph Stetter, TransducerTech
• Dr. Dan Laser, CEO Wave80
• Dr. Ian Gibbons , Director Business Development, ImmPORT Therapeutics

About nanoSIG:
nanoSIG, is the leading business membership organization focused on the commercial development of nanotechnology. NanoSIG promotes nano business networking by bringing together investors with inventors and creating a forum where all constituencies can exchange contacts and information and enable deals. See www.nanosig.org

Chair NanoInvestment & Commercialization Forum:
Brain Sefton
408-480-0463
bsefton@nanosig.org
www.nanosig.org

Press Contact:
Sandra Kay Helsel, Ph.D.
SK Helsel & Associates
520-325-4636
skhelsel@skhelsel.com
www.skhelsel.com

# # #